Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | APEX1 | P27695 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27466670 | 0.98 | ALDH1A1 (0.44) | ALDH1A1CYP2C9MAPTAPEX1KDM4E | |
| SCHEMBL9114515 | 0.94 | ALDH1A1 (0.58) | ALDH1A1CYP2C9 | |
| Acrylonitrile SCHEMBL6554745 | 0.88 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL4947083 | 0.86 | ALDH1A1 (0.58) | ALDH1A1CYP2C9 | |
| SCHEMBL10449919 | 0.85 | ALDH1A1 (0.42) | ALDH1A1MAPTEGLN1LMNANPSR1 | |
| Phthalic Acid SCHEMBL16932936 | 0.83 | ALDH1A1 (0.42) | ALDH1A1CYP2C9APEX1KDM4ELMNA | |
| SCHEMBL23088631 | 0.83 | ALDH1A1 (0.46) | ALDH1A1MAPTKDM4EEGLN1 | |
| Acrylic Acid Ethyl Ester SCHEMBL9067599 | 0.82 | NPSR1 (0.38) | ALDH1A1NPSR1 | |
| SCHEMBL195064 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAPTEGLN1LMNANPSR1 | |
| SCHEMBL11696200 | 0.81 | CTH (0.33) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1624 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180978-A1 | PREPARATIONS COMPRISING PROBIOTIC STRAINS AND L-TRYPTOPHAN | EVONIK OPERATIONS GMBH (DE) | 2024-06-06 | — | — | US | claimed |
| WO-2024119044-A2 | ADRULIPASE COMPOSITIONS | First Wave BioPharma, Inc. (US) | 2024-06-06 | — | — | WO | claimed |
| US-20240156882-A1 | PREPARATIONS COMPRISING PROBIOTIC STRAINS AND ANTHOCYANINS | EVONIK OPERATIONS GMBH (DE) | 2024-05-16 | — | — | US | claimed |
| US-11975103-B2 | Compositions of midodrine and methods of using the same | XENAMED CORP. (US) | 2024-05-07 | — | — | US | claimed |
| EP-4301385-A1 | PREPARATIONS COMPRISING PROBIOTIC STRAINS AND ANTHOCYANINS | Evonik Operations GmbH (DE) | 2024-01-10 | — | — | EP | claimed |
| EP-4301163-A1 | PREPARATIONS COMPRISING PROBIOTIC STRAINS AND L-TRYPTOPHAN | Evonik Operations GmbH (DE) | 2024-01-10 | — | — | EP | claimed |
| CN-114126590-B | Pharmaceutical preparation and method for producing the same | 富士制药工业股份有限公司 | 2024-01-05 | — | — | CN | claimed |
| US-20230398173-A1 | Delayed Release Compositions of Linaclotide | IRONWOOD PHARMACEUTICALS INC (US) | 2023-12-14 | — | — | US | claimed |
| WO-2023213584-A1 | A METHOD OF CELL REJUVENATION | EVONIK OPERATIONS GMBH (DE) | 2023-11-09 | — | — | WO | claimed |
| CN-116942565-A | Dispersion liquid and preparation method and application thereof | 宁波爱诗化妆品有限公司 | 2023-10-27 | — | — | CN | claimed |
| WO-2008065502-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON A) NANOPARTICLES COMPRISING ENTERIC POLYMERS AND B) CASEIN | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | claimed |
| WO-2008065506-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES COMPRISING ENTERIC POLYMERS AND CASEIN | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | claimed |
| CN-101190401-A | Hydrophilic polyvinylidene fluoride hollow fiber microporous membrane and preparation method thereof | HAINAN LISHENG WATER PURIFICAT (CN) | 2008-06-04 | — | — | CN | claimed |
| WO-2007127630-A1 | CONTROLLED RELEASED PREPARATIONS OF OXCARBAZEPINE HAVING SIGMOIDAL RELEASE PROFILE | SUPERNUS PHARMACEUTICALS, INC (US) | 2007-11-08 | — | — | WO | claimed |
| CN-101066525-A | Process of preparing micron level ordered porous aza titania microsphere | UNIV WUHAN ENGINEERING (CN) | 2007-11-07 | — | — | CN | claimed |
| US-20070254033-A1 | comprise solubility-and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles; controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration | SUPERNUS PHARMACEUTICALS, INC. | 2007-11-01 | — | — | US | claimed |
| CN-1730116-A | Conduct assembly and injection molding technological process and making equipment thereof | BECTON DICKINSON CO (US) | 2006-02-08 | — | — | CN | claimed |
| US-20040220250-A1 | Novel oral dosage form for carvedilol | Boehringer Mannhein Pharmaceutical Corporation | 2004-11-04 | — | — | US | claimed |
| US-5431920-A | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents | MERCK FROSST, CANADA, INC. (CA) | 1995-07-11 | — | — | US | claimed |
| US-4497847-A | MONO AND DIESTERS OF GLYCEROL AND SATURATED CARBOXYLIC ACIDS AS PLASTICIZERS | SANKYO COMPANY, LIMITED (JP) | 1985-02-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398173-A1 | Delayed Release Compositions of Linaclotide | LPXN, LHCGR, BRS3 | ALDH1A1 3926/4885CYP2C9 1966/4885MAPT 3995/4885 |
| US-11975103-B2 | Compositions of midodrine and methods of using the same | PDE3A, PDE5A, PDE3B | ALDH1A1 3934/4885CYP2C9 168/4885MAPT 2275/4885 |
| US-20040220250-A1 | Novel oral dosage form for carvedilol | ADRB1, ADRB2, ADRB3 | ALDH1A1 929/4885CYP2C9 63/4885MAPT 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.